Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of REGN7075 alone and with cemiplimab in advanced solid tumors
MOH_2024-08-07_013569Phase 2Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of dalmitamig and cemiplimab in Nonhematologic neoplasms (3 arms), sponsored by Regeneron Pharmaceuticals. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
dalmitamigcemiplimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2024-08-07_013569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-08-07_013569.